Growing evidence suggests that the gut microbiome and diabetes are intricately linked, with gut bacteria influencing glucose metabolism, insulin resistance, and inflammation. Dysbiosis, or microbial imbalance, has been associated with an increased risk of type 2 diabetes and metabolic dysfunction. Short-chain fatty acids produced by beneficial bacteria play a role in improving insulin sensitivity and regulating appetite. Probiotics, prebiotics, and dietary interventions targeting gut microbiota composition offer promising therapeutic potential. Advances in metagenomics and microbiome research continue to uncover mechanisms by which gut flora modulate metabolic health. Understanding these interactions may lead to novel microbiome-based strategies for diabetes prevention and treatment.
Mahir Khalil Ibrahim Jallo
Gulf Medical University, Canada
Yong Xiao Wang
Albany Medical College, United States
F Buck Willis
Belize Bible College, Belize
Sujith Rajan
NYU Long Island School of Medicine, United States
Amy Gutman
AdventHealth; Tough Love MD, United States
Paraskevi Theofilou
Hellenic Open University, Greece
Teji S Dhami
Boost your Health and Wellness, United StatesSubmit your abstract Today
Title : Adipose MTP deficiency protects against hepatic steatosis by upregulating PPAR activity
Sujith Rajan, NYU Long Island School of Medicine, United States
Title : Important roles and mechanisms of novel calcium signaling in diabetes-induced vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : Does winter melon (Benincasa hispida) improves nutritional values and ameliorating glycaemic parameters?
Wan Rosli Wan Ishak, Universiti Sains Malaysia, Malaysia
Title : Diabetes reduction (pre-diabetes and type 2) with integrative medicine
F Buck Willis, Belize Bible College, Belize
Title : The menopausal mind: Reframing female senescence as a neuroendocrine disorder with root cause management strategies
Amy Gutman, AdventHealth; Tough Love MD, United States
Title : Bridging the gap: Coaching patients on GLP-1s for sustainable outcomes beyond the prescription
Keith Hersey, Master Your GLP-1, United States